Why TC BioPharm (TCBP) Stock Is Down 40%

TC BioPharm Ltd TCBP shares are trading lower by 44% to $2.00 Wednesday morning after the company announced the pricing of an offering of 2 million units at $1 per unit.

The clinical-stage biotech company also issued 2 million Series G warrants with an exercise price of £0.78. TC BioPharm plans to use the funds raised from the offering to support its upcoming clinical trial for relapse/refractory Acute Myeloid Leukemia, as well as for ongoing operating expenses and working capital.

Read Also: UBS Q2 Earnings Beats: Wealth Management Shines, Cost Savings Accelerate & More

Should I Sell My TCBP Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of TC BioPharm have decreased by 96.36% in the past year. An investor who bought shares of TC BioPharm at the beginning of the year would take a loss of $27.65 per share if they sold it today. The stock has fallen 59.44% over the past month, meaning an investor who bought shares on Jul. 1 would see a capital loss of $5.26.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. TC BioPharm (Holdings) stock currently has an RSI of 20.56, indicating oversold conditions.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.